36 terminated. 36 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 36 | Terminated 36 |
| Phase 1 | 6 | Terminated 6 |
| Phase 3 | 2 | Terminated 2 |
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) BI 3720931, Placebo, Inhaler - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | Boehringer Ingelheim | 5 | 2024-11-04 | 2026-04-15 |
| A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF Anakinra - Cystic Fibrosis, 10011762 | Phase 2 | Terminated | Heidelberg University | 33 | 2022-12-01 | 2026-10-08 |
| Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus RESP301 - Cystic Fibrosis | Phase 2 | Terminated | Papworth Hospital NHS Foundation Trust | 6 | 2021-11-01 | 2024-05-10 |
| Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis ABBV-576, Galicaftor, Placebo - Cystic Fibrosis (CF) | Phase 2 | Terminated | AbbVie | 48 | 2021-09-20 | 2024-07-16 |
| Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis Treatment with polyethylene glycol (Macrogol 4000) - Cystic Fibrosis | Phase 2 | Terminated | University Hospital, Bordeaux | 23 | 2020-09-29 | 2026-06-22 |
| Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis ARO-ENaC, Placebo - Cystic Fibrosis, Pulmonary | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 43 | 2020-07-30 | 2025-12-17 |
| A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1 BI 1265162, Placebo - Cystic Fibrosis | Phase 2 | Terminated | Boehringer Ingelheim | 52 | 2019-09-16 | 2021-06-04 |
| Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection Molgramostim nebulizer solution, PARI eFlow nebulizer system - Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF) | Phase 2 | Terminated | Savara Inc. | 14 | 2019-06-20 | 2023-01-10 |
| A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis OligoG DPI - Cystic Fibrosis | Phase 2 | Terminated | AlgiPharma AS | 15 | 2019-05-16 | 2024-10-28 |
| The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis PC945 - Aspergillosis, Cystic Fibrosis | Phase 2 | Terminated | Pulmocide Ltd | 4 | 2019-04-03 | 2021-07-16 |
| Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis) Ravicti low dose, Placebo - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | National Jewish Health | 16 | 2018-12-02 | 2026-04-17 |
| Losartan and Inflammation in Cystic Fibrosis Losartan, placebo - Cystic Fibrosis | Phase 2 | Terminated | University of Miami | 7 | 2017-11-11 | 2020-11-27 |
| Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients Nitric Oxide 160 ppm - Cystic Fibrosis | Phase 2 | Terminated | Novoteris, LLC | 49 | 2017-02-22 | 2021-03-05 |
| Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance PBI4050, Placebo - Cystic Fibrosis | Phase 2 | Terminated | Liminal BioSciences Ltd. | 11 | 2017-01-03 | 2020-12-08 |
| Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease Oral Aztreonam, Nasal Aztreonam, Nasal Placebo - Cystic Fibrosis | Phase 2 | Terminated | Virginia Commonwealth University | 5 | 2017-01-01 | 2021-01-28 |
| Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations VX-561, Placebo, IVA - Cystic Fibrosis | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 11 | 2016-12-01 | 2020-08-26 |
| Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis Andecaliximab, Placebo - Cystic Fibrosis | Phase 2 | Terminated | Gilead Sciences | 6 | 2016-11-04 | 2018-08-17 |
| Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Roscovitine, Placebo - Cystic Fibrosis | Phase 2 | Terminated | University Hospital, Brest | 49 | 2016-02-22 | 2025-12-12 |
| Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis sodium nitrite - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | Schmidhofer, Mark, MD | 4 | 2016-02-01 | 2024-06-24 |
| Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC) MAG-DHA, Placebo - Cystic Fibrosis | Phase 2 | Terminated | SCF Pharma | 11 | 2015-10-01 | 2017-10-04 |
Showing 20 of 36. Sign in to see all of them.
Mycobacterium Infections, Nontuberculous (2) · Aspergillosis (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Digestive System Diseases (1) · Fibrosis (1) · Genetic Diseases, Inborn (1) · Hyperglycemia (1) · Infant, Newborn, Diseases (1) · Infections (1) · Lung Diseases (1) · Pancreatic Diseases (1) · Pathologic Processes (1) · Respiratory Tract Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (36) · Digestive System Diseases (35) · Genetic Diseases, Inborn (35) · Infant, Newborn, Diseases (35) · Lung Diseases (35) · Pancreatic Diseases (35) · Respiratory Tract Diseases (35) · Bacterial Infections and Mycoses (4) · Infections (4) · Actinomycetales Infections (2) · Bacterial Infections (2) · Gram-Positive Bacterial Infections (2) · Mycobacterium Infections (2) · Mycoses (2) · Aspergillosis (1)
ivacaftor (2) · 4-phenylbutyric acid (1) · Aztreonam (1) · Dipeptidyl-Peptidase IV Inhibitors (1) · GLPG2222 (1) · Genistein (1) · Gentamicins (1) · Glycine (1) · Insulin Aspart (1) · Insulin Detemir (1) · Interleukin 1 Receptor Antagonist Protein (1) · Losartan (1) · Minocycline (1) · Mupirocin (1) · Nebulizers and Vaporizers (1)
Boehringer Ingelheim (3) · Vertex Pharmaceuticals Incorporated (2) · AbbVie (1) · Actegy Ltd. (1) · Actelion (1) · AlgiPharma AS (1) · Arrowhead Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · Bayer (1) · Children's Hospital of Philadelphia (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Gilead Sciences (1) · Heidelberg University (1) · Instituto Nacional de Enfermedades Respiratorias (1) · Liminal BioSciences Ltd. (1)
United States (17) · France (8) · United Kingdom (8) · Canada (7) · Belgium (5) · Germany (5) · Australia (4) · Spain (4) · Netherlands (3) · New Zealand (2) · Hungary (1) · Ireland (1) · Italy (1) · Mexico (1) · Romania (1)
Aleksander Edelman, PhD (1) · Andre Cantin, md (1) · Antoinette Moran, MD (1) · Bruce K Rubin, MD (1) · Chris Goss, MD (1) · Christian Domingo-Ribas, MD (1) · Graydon Meneilly, MD (1) · Isabelle Sermet, MD; PhD (1) · Jerry Nick, MD (1)
PMID 15618584, PMID 18006891, PMID 22383668, PMID 22863555, PMID 25781052, PMID 27852955, PMID 29246256, PMID 29861448, PMID 33293212, PMID 33313307, PMID 33331662, PMID 34385272, PMID 34419414, PMID 34961705, PMID 36511181, PMID 37983082
2019 (2), 2009 (1), 2015 (1), 2018 (1), 2023 (1)